Cohance Lifesciences Limited announced the appointment of Mr. Sisir K. Mishra as the new Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP). The appointment, approved by the Board based on the Nomination and Remuneration Committee’s recommendation, will be effective from April 9, 2026. Mr. Mishra brings over two decades of diverse experience across secretarial, legal, governance, CSR, and ESG functions in various sectors.
Official Board Approval for Key Personnel Change
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has formally disclosed a key managerial change following its Board meeting held on Monday, March 30, 2026. The Board has approved the appointment of Mr. Sisir K. Mishra to fill the critical roles of Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP).
This appointment is effective starting April 9, 2026. The decision was made subsequent to the recommendation provided by the Nomination and Remuneration Committee.
Profile of the New Company Secretary
The incoming Company Secretary, Mr. Sisir K. Mishra, is a highly qualified professional, holding the designation of a Fellow Member of the Institute of Company Secretaries of India (ICSI) and possessing an LL.M. from Osmania University.
His extensive career spans over two decades, during which he has developed expertise across corporate secretarial, legal, governance, CSR, and ESG functions. His experience covers diversified industries including infrastructure, manufacturing, IT, and power. Notably, Mr. Mishra has significant experience managing board governance, regulatory interface, fundraising, IPO readiness, and compliance systems.
Prior to joining Cohance Lifesciences, his service history includes roles as Company Secretary at prominent entities such as NCC Limited, Paradeep Phosphates Limited, Deccan Cements Limited, and the KSK Group.
Term and Disclosure Details
The term for this appointment is specified as Not applicable. Furthermore, the company confirmed that there are no disclosed relationships between the appointee and any existing directors of the Company.
Source: BSE
